13F Holdings
中文EN

CLLS Cellectis S.A. IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1627281 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY75.8%
TTM net income YoY-83.9%
TTM EPS YoY-63.4%
Revenue 3-yr CAGR56.1%
Net income 3-yr CAGR—

Margins

Gross margin100.0%
Operating margin-45.3%
Net margin-92.7%
FCF margin-57.2%
EBITDA margin-17.8%

Returns

ROE-65.3%
ROA-19.1%
ROIC (approx.)-2,430.7%
Asset turnover0.21x

Leverage & solvency

Liabilities / assets76.6%
Debt / equity0.00x
Current ratio—
Interest coverage-0.65x

Cash quality & payout

Operating cash flow / net income0.58x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue3.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q22025-06-302024Q22024-06-302023Q4*2023-12-312023Q3*2023-09-302023Q22023-06-302022Q22022-06-302021Q22021-06-302020Q22020-06-30
Income statement
Revenue$16.73M$8.06M——$178,000$1.31M$11.18M$2.90M
Cost of revenue————$55,000$329,000$11.75M$5.83M
Gross profit————$123,000$978,000-$578,000-$2.93M
R&D expense$23.08M$23.52M——$22.20M$25.63M$31.15M$22.86M
SG&A expense$5.08M$3.88M——$3.95M$4.83M$9.34M$9.07M
Operating income-$9.59M-$17.21M-$29.58M-$20.67M-$23.62M-$27.31M-$37.48M-$33.03M
Interest expense$19.70M$16.65M$17.56M$1.62M$16.28M$1.69M——
Pretax income—-$25.50M——————
Income tax$0-$193,000$6,000$107,000$258,000$0$0$0
Net income-$23.74M-$25.27M-$41.80M-$18.55M-$11.71M-$18.95M-$39.92M-$32.26M
EBITDA—————-$22.20M-$34.10M-$30.88M
EPS (basic)-0.24-0.28——-0.20-0.42-0.88-0.76
EPS (diluted)-0.24-0.28——-0.20-0.42-0.88-0.76
Weighted avg. shares (diluted)—89.85M——55.58M———
Balance sheet
Cash & equivalents$59.81M$149.04M$136.71M—$84.39M$129.44M$248.23M$260.71M
Short-term investments$136.10M$119.00M——————
Receivables$8.78M$9.74M$569,000—$422,000$2.60M$3.88M$3.98M
Inventory——————$2.47M$5.71M
Current assets—————$175.17M$280.35M$347.93M
PP&E, netmay include right-of-use assets (IFRS)$42.79M$50.37M$54.68M—$59.23M$76.52M$79.48M$52.65M
Intangibles$1.15M———————
Total assets$353.97M$407.15M$334.27M$209.70M$227.67M$320.88M$457.56M$472.70M
Current liabilities$167.43M$159.63M$155.14M$43.95M$42.05M$55.28M$51.45M$53.05M
Total liabilities$256.86M$258.54M$249.57M$133.58M$131.12M$140.36M$155.24M$127.64M
Shareholders' equity$97.11M$148.61M$84.69M$76.12M$96.56M$168.93M$275.87M$307.61M
Shares outstanding100.33M100.09M71.75M—55.58M45.51M45.46M42.49M
Cash flow statement
Operating cash flow————————
Depreciation & amortization—————$5.11M$3.38M$2.15M
Stock-based compensation$1.28M$830,000$5.13M-$3.17M$100,000———

Free plan shows the latest 8 periods; Pro shows all 9 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.